

wherein R<sup>1</sup> is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

R<sup>2</sup> is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

R<sup>3</sup> is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys and Tyr;

R<sup>4</sup> is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, Ala, homoSer and azaTyr;

R<sup>5</sup> is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R<sup>6</sup> is selected from the group consisting of His, Arg or 6-NH<sub>2</sub>-Phe;

R<sup>7</sup> is selected from the group consisting of Pro or Ala; and

R<sup>8</sup> is selected from the group consisting of Phe, Phe(Br), Ile and Tyr; excluding sequences including R<sup>4</sup> as an N-terminal Tyr group, and

wherein the active agent is not SEQ ID NO:1 or SEQ ID NO:19,

for a time and under conditions effective to augment erythropoiesis, wherein the method is used to treat anemia associated with a condition selected from the group consisting of chronic renal failure, end-stage renal disease, renal transplantation, cancer, acquired immune deficiency syndrome, chemotherapy, radiotherapy, bone marrow transplantation.

53.(New) The method of claim 43 wherein the active agent comprises a sequence of at least four contiguous amino acids of groups R<sup>1</sup>-R<sup>8</sup> in the sequence of general formula I.

54.(New) The method of claim 43 wherein the active agent comprises a sequence of at least five contiguous amino acids of groups R<sup>1</sup>-R<sup>8</sup> in the sequence of general formula I.

55.(New) The method of claim 43 wherein the active agent consists of a sequence of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

56.(New) The method of claim 43 wherein the active agent consists of a sequence of at least four contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

57.(New) The method of claim 43 wherein the active agent consists of a sequence of at least five contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

58.(New) The method of claim 43 wherein the active agent comprises a sequence selected from the group consisting of angiotensinogen, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39.

59.(New) The method of claim 43 wherein the active agent consists of a sequence selected from the group consisting of angiotensinogen, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID